IPI-926 is a novel, proprietary, semi-synthetic derivative of the natural product, cyclopamine, that inhibits the Hedgehog signaling pathway by binding to the Smoothened receptor. When systemically administered in multiple preclinical animal models, IPI-926 has shown potent and selective inhibition of the Hedgehog pathway, anti-tumor activity, and attractive pharmacologic properties including oral bioavailability and extended half-life. We anticipate commencing clinical development of IPI-926 in 2008.

In June 2007, Infinity was issued a patent (U.S. Patent No. 7,230,004) by the United States Patent and Trademark Office broadly covering the composition of matter of a genus of compounds, including IPI-926, useful for modulating the Hedgehog signaling pathway.